Efficacy of anti-VEGF agents in the treatment of elderly hepatocellular carcinoma: a systematic review

Li, Xiaofei; Zhang, Daofu; Guan, Shan; Ye, Weiwei; Liu, Liwen; Lou, Lianqing

doi:10.18632/oncotarget.21452

Cited by 3 publications

(4 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VEGF levels in HCC patients are higher than in patients with chronic hepatitis and cirrhosis. The increase of VEGF is negatively correlated with the prognosis of liver cancer [87,88] . The current only FDA approved first line therapeutic drug for advanced HCC, sorafenib, is also a tyrosine kinase inhibitor (TKI) directed against the VEGF family.…”

Section: Vegf Pathwaymentioning

confidence: 99%

Understanding the inflammation-cancer transformation in the development of primary liver cancer

Chen¹,

Hu²,

Xu³

et al. 2018

View full text Add to dashboard Cite

Primary liver cancer is one of the leading causes of cancer-related deaths worldwide. China has more than 55% liver cancer cases globally. The development of hepatocellular carcinoma (HCC) was caused by a variety of risks factors, including chronic inflammation by virus, alcohol consumption and non-alcoholic steatohepatitis. Emerging evidence has notarized inflammation as a critical component of HCC progression. The development of HCC is a multistep process which may originate from liver chronic injury and inflammation to subsequent fibrosis and/or cirrhosis and finally HCC. A large number of studies indicate that chemokines and cytokines are candidates linking molecules between inflammation and liver cancer. Here, we will describe a few of the key cytokines and chemokines and signal pathways which are involved in the inflammation of HCC. Inhibitors of inflammation for the prevention and overcoming antitumor immunity for treatment of liver cancer are promising candidates for the future management of patients with HCC.

show abstract

Section: Vegf Pathwaymentioning

confidence: 99%

Understanding the inflammation-cancer transformation in the development of primary liver cancer

Chen¹,

Hu²,

Xu³

et al. 2018

View full text Add to dashboard Cite

show abstract

“…As the dominant clinically available targeting reagents for HCC, sorafenib and regorafenib, acting on Raf/mitogen-activated protein kinase/extracellular signal-regulated kinase (RAF/MEK/ERK) and VEGF signaling pathways, did not result in remarkable improvement in the patient's outcome as other targeting reagents did in breast cancer or lung cancer [11][12][13]. The accumulating clinical and biological databases of cancer disease provide reliable source to dig out and verify new clues for cancer diagnosis and treatment [14].…”

Section: Introductionmentioning

confidence: 99%

Exploration of Combinational Therapeutic Strategies for HCC Based on TCGA HCC Database

Yan¹,

Li²,

Zhou³

et al. 2022

Oncologie

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most deadly types of cancer. Sorafenib is currently the only available first-line molecular targeted drug approved by the FDA for HCC. However, primary and secondary resistance is often encountered with treatment with sorafenib. Genomic alterations found in HCC represent potential targets to develop new drugs or new combinational strategies against this type of cancer. Here we analyzed genomic alterations from the TCGA database of HCC samples and the corresponding targeted drugs available to the clinic to identify candidate drugs that might hold promise when used in combination with sorafenib. Our results revealed that IL6, JAK1, LEPR and RAF1 related pathways were commonly altered in HCC, which have targeted drugs available in medical practice. Fourteen genes with available targeting drugs were frequently altered in HCC. The pathways and gene targets with the respective targeted drugs warrant further evaluation in clinical trials to determine their therapeutic value in the treatment of HCC, alone or in combination with sorafenib. In summary, the analysis of TCGA, identified a series of pathways with targeted drugs available that were altered in HCC. Combination treatment with specific targeted drugs, depending on the altered pathways found in individuals may provide a better treatment strategy that will ultimately improve individual patient survival.

show abstract

“…2 With the advent of molecularly targeted therapeutic agents (MTAs), the treatment of HCC has substantially improved. 3 In March 2018, lenvatinib (LEN), an MTA, was approved for the treatment of unresectable HCC following sorafenib and regorafenib treatment, as the first-line treatment for patients with unresectable HCC in the United States of America, the European Union, Japan, and China, based on the results of the REFLECT trial, a global multicenter randomized phase 3 trial of LEN for HCC. [4][5][6][7] It has been reported that treatment with LEN results in a decrease in tumor blood flow during the early stages of administration.…”

Section: Introductionmentioning

confidence: 99%

“… 2 With the advent of molecularly targeted therapeutic agents (MTAs), the treatment of HCC has substantially improved. 3 …”

Section: Introductionmentioning

confidence: 99%

Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast‐enhanced ultrasound

et al. 2021

View full text Add to dashboard Cite

Background: The antitumor effect of a drug is considered to be associated with a decrease in tumor blood flow.Aims: We investigated whether the efficacy of lenvatinib (LEN) could be accurately assessed by measuring blood flow in hepatocellular carcinoma (HCC) during early treatment stages.Methods and results: Blood flow changes and treatment results of 19 patients who underwent contrast-enhanced ultrasound (CEUS), before and after LEN administration, in Kurume University Hospital from July 2018 to June 2020 were examined.Blood flow was evaluated after the intravenous administration of perflubutane (0.015 ml/kg). The vascular phase was photographed and used as RAW data, and timeintensity curve analysis was used to obtain the region of interest (ROI) on the entire tumor nodule and quantify tumor blood flow. The evaluation was performed before and 1 and 4 weeks after LEN administration. Mean ± standard deviation (SD) values of the brightness of blood flow in the background liver before and 1 and 4 weeks after LEN administration were 2.84 Â 10 À4 ± 2.94 Â 10 À4 , 3.07 Â 10 À4 ± 3.79 Â 10 À4 , and 10.0 Â 10 À4 ± 20.8 Â 10 À4 dB, respectively. Blood flow in the background liver did not significantly decrease at 1 and 4 weeks compared with that before treatment. Mean ± SD values of the brightness of blood flow in HCC before and 1 and 4 weeks after administration were 3.49 Â 10 À3 ± 4.58 Â 10 À3 , 1.16 Â 10 À3 ± 1.57 Â 10 À3 , and 6.39 Â 10 À3 ± 22.8 Â 10 À3 dB, respectively. Blood flow in HCC after 1 week was significantly lower than that before administration (p = .0192). The therapeutic effects were significantly higher in the group with ≥50% blood flow reduction in HCC at 1 week after administration (p = .0038) and the group with reduced blood flow in HCC at 4 weeks after administration (p = .0051) than those before administration.

show abstract

Efficacy of anti-VEGF agents in the treatment of elderly hepatocellular carcinoma: a systematic review

Cited by 3 publications

References 44 publications

Understanding the inflammation-cancer transformation in the development of primary liver cancer

Understanding the inflammation-cancer transformation in the development of primary liver cancer

Exploration of Combinational Therapeutic Strategies for HCC Based on TCGA HCC Database

Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast‐enhanced ultrasound

Contact Info

Product

Resources

About